Allison Dorval, Chief Financial Officer at Verve Therapeutics, Inc. (VERV), sold 3,350 shares at $4.15 ($14K) on 2025-04-02, disclosed to the SEC on 2025-04-03.
Open-market sale of $14k VERV by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| VERV | SELL | 2024-12-03 | $3K | — | Filing → |
| PBYI | SELL | 2024-06-17 | $37K | — | Filing → |
| VERV | SELL | 2023-12-01 | $6K | — | Filing → |